文献速递血栓与止血

伴肥厚性滑膜的血液病患者接受强化FVIII替代治疗:一项随机研究

Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study.
PubMed 文献 · J Thromb Haemost · 2024-10-28

这项随机、开放标签研究将伴肥厚性滑膜(HS)的血液病患者随机分入药代动力学驱动的强化治疗组(目标FVIII谷浓度8%~12%)或标准治疗组(目标3%~5%),强化组HS减轻/消退率为35.9%,标准组为8.4%,Cox回归显示强化治疗与HS减轻/消退相关(HR 4.75)。

要点

  • 强化组HS减轻/消退率35.9%,标准组8.4%。
  • 强化组HS完全消退率25.6%,标准组2.8%。
  • 强化治疗与HS减轻/消退相关,HR 4.75(95%CI 1.36-16.57,P=.014)。

核心结论

  • 在伴肥厚性滑膜的血液病患者中,强化FVIII替代治疗组的HS减轻/消退率约为标准治疗组的5倍,HS完全消退率约为10倍。

研究设计与样本

  • 随机、开放标签研究,伴HS的血液病患者随机接受药代动力学驱动的强化治疗(目标FVIII谷浓度8%~12%)或标准治疗(目标3%~5%)。
  • 强化治疗组39例,标准治疗组36例。

主要发现

  • 强化组年出血率低于标准组,年出血率为零的比例高于标准组。
  • 强化组HS减轻/消退率为35.9%,标准组为8.4%。
  • 强化组HS减轻率10.3%、完全消退率25.6%,标准组分别为5.6%和2.8%。
  • Cox回归显示强化治疗与HS减轻/消退相关(HR 4.75,95%CI 1.36-16.57,P=.014),与HS完全消退相关(HR 10.79,95%CI 1.38-84.45,P=.023)。
  • 对127个伴HS关节(肘54个、膝41个、踝32个)的分析结果一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertrophic synovium (HS) is a marker of disease activity in persons with hemophilia (PwH). Although some recommendations suggest intensifying prophylaxis in PwH with HS, no validated schedules are available. OBJECTIVES: We explored the efficacy of intensive factor VIII (FVIII) replacement treatment in PwH with HS. METHODS: In a randomized, open-label study, PwH with HS were randomized to receive pharmacokinetics-driven prophylaxis targeting a FVIII trough level of 8% to 12% (intensive treatment arm [ITA]) or 3% to 5% (standard treatment arm [STA]). The primary outcome was HS reduction/resolution in the 2 treatment arms. RESULTS: A total of 39 PwH were randomized to ITA and 36 to STA. During the study, we found a lower annual bleeding rate and a higher rate of annual bleeding rate zero in the ITA than in the STA. HS reduction/resolution was reported in 35.9% of cases in the ITA and 8.4% in the STA. In detail, in the ITA ,10.3% achieved HS reduction and 25.6% complete HS resolution, as compared to 5.6% and 2.8% in the STA. Cox regression showed that ITA was associated with HS reduction/resolution (hazard ratio: 4.75; 95% CI: 1.36-16.57; P = .014) and HS complete resolution (hazard ratio: 10.79; 95% CI: 1.38-84.45; P = .023). The analysis of the 127 joints with HS (54 elbows, 41 knees, and 32 ankles) consistently confirmed similar results. CONCLUSION: In this randomized study, we found a ∼5-fold higher rate of HS reduction/resolution and a ∼10-fold higher rate of HS resolution in the ITA than in the STA.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Di Minno MND, Calcaterra IL, Baldacci E, et al. Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study. J Thromb Haemost. 2024. PMID: 39476971. doi:10.1016/j.jtha.2024.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。